Omega Therapeutics, Inc.
OMGAQ
$0.0305
-$0.0066-17.79%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 8.10M | 6.31M | 4.94M | 3.10M | 2.84M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.10M | 6.31M | 4.94M | 3.10M | 2.84M |
| Cost of Revenue | 46.28M | 49.48M | 62.28M | 66.95M | 80.78M |
| Gross Profit | -38.18M | -43.16M | -57.34M | -63.86M | -77.94M |
| SG&A Expenses | 35.97M | 37.47M | 37.55M | 36.40M | 32.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 82.25M | 86.95M | 99.83M | 103.36M | 113.37M |
| Operating Income | -74.15M | -80.63M | -94.89M | -100.26M | -110.53M |
| Income Before Tax | -73.09M | -78.90M | -92.28M | -97.43M | -108.04M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -73.09 | -78.90 | -92.28 | -97.43 | -108.04 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -73.09M | -78.90M | -92.28M | -97.43M | -108.04M |
| EBIT | -74.15M | -80.63M | -94.89M | -100.26M | -110.53M |
| EBITDA | -72.41M | -78.89M | -93.25M | -98.69M | -109.00M |
| EPS Basic | -1.33 | -1.43 | -1.67 | -1.81 | -2.09 |
| Normalized Basic EPS | -0.83 | -0.89 | -1.05 | -1.13 | -1.30 |
| EPS Diluted | -1.33 | -1.44 | -1.68 | -1.81 | -2.09 |
| Normalized Diluted EPS | -0.83 | -0.89 | -1.05 | -1.13 | -1.30 |
| Average Basic Shares Outstanding | 220.60M | 220.58M | 220.51M | 215.98M | 208.73M |
| Average Diluted Shares Outstanding | 220.60M | 220.58M | 220.51M | 215.98M | 208.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |